-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, relevant departments organized a work conference on centralized drug procurement in Nanjing.
Insulin may become the first batch of "special purchases" products.
In addition, there are also news that biologics and proprietary Chinese medicines have entered mass purchases, and the accuracy of the news is not yet clear.
It is reported that there are currently 86 varieties that meet the fifth batch of centralized procurement rules, including 33 injection varieties, 3 biosimilar drugs and multiple insulin varieties.
The three biosimilar drugs that are eligible for collection are adalimumab, bevacizumab, and rituximab.
As for the key insulin products that this centralized procurement focuses on, there are currently a number of domestic manufacturers of 3 or more (mainly concentrated in the second and third generation insulins).